Advertisement
American Journal of Kidney Diseases

C3 Glomerulonephritis Associated With Monoclonal Gammopathy: A Case Series

Published:April 29, 2013DOI:https://doi.org/10.1053/j.ajkd.2013.02.370

      Background

      C3 glomerulonephritis (GN) is a proliferative GN resulting from glomerular deposition of complement factors due to dysregulation of the alternative pathway of complement. Dysregulation of the alternative pathway of complement may occur as a result of mutations or functional inhibition of complement-regulating proteins. Functional inhibition of the complement-regulating proteins may result from a monoclonal gammopathy.

      Study Design

      Case series.

      Setting & Participants

      32 Mayo Clinic patients with C3 GN, 10 (31%) of whom had evidence of a monoclonal immunoglobulin in serum.

      Outcomes

      Clinical features, hematologic and bone marrow biopsy findings, kidney biopsy findings, kidney measures, complement pathway abnormalities, treatment, and follow-up of patients with C3 GN that was associated with a monoclonal gammopathy.

      Results

      Mean age of patients with C3 GN associated with monoclonal gammopathy was 54.5 years. Bone marrow biopsy done in 9 patients revealed monoclonal gammopathy of undetermined significance in 5 patients, small lymphocytic lymphoma/chronic lymphocytic leukemia in one patient, and no abnormal clones in the other 3 patients. Kidney biopsy showed membranoproliferative GN with bright capillary wall C3 staining in all 10 patients. Evaluation of the alternative pathway of complement showed abnormalities in 7 of 9 patients tested. No mutation in complement-regulating proteins was detected in any patient. As an index case, one patient with C3 GN and chronic lymphocytic leukemia was treated with rituximab, cyclophosphamide, vincristine, and prednisone, and one patient with C3 GN and monoclonal gammopathy of undetermined significance was treated with dexamethasone and bortezomib. Both patients showed significant decreases in hematuria and proteinuria and stabilization of kidney function.

      Limitations

      Studies to show evidence of direct activation of the alternative pathway by monoclonal immunoglobulin were not done.

      Conclusions

      The study highlights the association of C3 GN and monoclonal gammopathy, in particular in the older population, and the importance of targeting the underlying hematologic malignancy as an approach to treating C3 GN.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sethi S.
        • Zand L.
        • Leung N.
        • et al.
        Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy.
        Clin J Am Soc Nephrol. 2010; 5: 770-782
        • Nasr S.H.
        • Satoskar A.
        • Markowitz G.S.
        • et al.
        Proliferative glomerulonephritis with monoclonal IgG deposits.
        J Am Soc Nephrol. 2009; 20: 2055-2064
        • Nasr S.H.
        • Valeri A.M.
        • Cornell L.D.
        • et al.
        Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution.
        Clin J Am Soc Nephrol. 2012; 7: 231-239
        • Lin J.
        • Markowitz G.S.
        • Valeri A.M.
        • et al.
        Renal monoclonal immunoglobulin deposition disease: the disease spectrum.
        J Am Soc Nephrol. 2001; 12: 1482-1492
        • Servais A.
        • Fremeaux-Bacchi V.
        • Lequintrec M.
        • et al.
        Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
        J Med Genet. 2007; 44: 193-199
        • Sethi S.
        • Fervenza F.C.
        • Zhang Y.
        • et al.
        C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
        Kidney Int. 2012; 82: 465-473
        • Sethi S.
        • Fervenza F.C.
        • Zhang Y.
        • et al.
        Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
        Clin J Am Soc Nephrol. 2011; 6: 1009-1017
        • Sethi S.
        • Fervenza F.C.
        • Zhang Y.
        • et al.
        Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement.
        Kidney Int. 2013; 83: 293-299
        • Zhang Y.
        • Meyer N.C.
        • Wang K.
        • et al.
        Causes of alternative pathway dysregulation in dense deposit disease.
        Clin J Am Soc Nephrol. 2012; 7: 265-274
        • Abrera-Abeleda M.A.
        • Nishimura C.
        • Frees K.
        • et al.
        Allelic variants of complement genes associated with dense deposit disease.
        J Am Soc Nephrol. 2011; 22: 1551-1559
        • Maga T.K.
        • Meyer N.C.
        • Belsha C.
        • Nishimura C.J.
        • Zhang Y.
        • Smith R.J.H.
        A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome.
        Nephrol Dial Transplant. 2011; 26: 739-741
        • Sethi S.
        • Gamez J.D.
        • Vrana J.A.
        • et al.
        Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway.
        Kidney Int. 2009; 75: 952-960
        • Fakhouri F.
        • Fremeaux-Bacchi V.
        • Noel L.-H.
        • Cook H.T.
        • Pickering M.C.
        C3 glomerulopathy: a new classification.
        Nat Rev Nephrol. 2010; 6: 494-499
        • Sethi S.
        • Fervenza F.C.
        Membranoproliferative glomerulonephritis: a new look at an old entity.
        N Engl J Med. 2012; 366: 1119-1131
        • Sethi S.
        • Nester C.M.
        • Smith R.J.H.
        Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.
        Kidney Int. 2012; 81: 434-441
        • Appel G.B.
        • Cook H.T.
        • Hageman G.
        • et al.
        Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.
        J Am Soc Nephrol. 2005; 16: 1392-1403
        • Smith R.J.H.
        • Alexander J.
        • Barlow P.N.
        • et al.
        New approaches to the treatment of dense deposit disease.
        J Am Soc Nephrol. 2007; 18: 2447-2456
        • Abrera-Abeleda M.A.
        • Nishimura C.
        • Smith J.L.H.
        • et al.
        Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease).
        J Med Genet. 2006; 43: 582-589
        • Zipfel P.F.
        • Skerka C.
        Complement regulators and inhibitory proteins.
        Nat Rev Immunol. 2009; 9: 729-740
        • Nasr S.H.
        • Valeri A.M.
        • Appel G.B.
        • et al.
        Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients.
        Clin J Am Soc Nephrol. 2009; 4: 22-32
        • Sepandj F.
        • Trillo A.
        Dense deposit disease in association with monoclonal gammopathy of unknown significance.
        Nephrol Dial Transplant. 1996; 11: 2309-2312
        • Sethi S.
        • Sukov W.R.
        • Zhang Y.
        • et al.
        Dense deposit disease associated with monoclonal gammopathy of undetermined significance.
        Am J Kidney Dis. 2010; 56: 977-982
        • Bridoux F.
        • Desport E.
        • Fremeaux-Bacchi V.
        • et al.
        Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?.
        Clin J Am Soc Nephrol. 2011; 6: 2165-2174
        • Kyle R.A.
        • Therneau T.M.
        • Rajkumar S.V.
        • et al.
        Prevalence of monoclonal gammopathy of undetermined significance.
        N Engl J Med. 2006; 354: 1362-1369
        • Touhard G.
        Monoclonal gammopathies and the kidney.
        in: Touhard G. Aucouturier P. Hermine O. Ronco P. Kluwer Academic Publishers, Norwell, MA2003: 95-117
        • Meri S.
        • Koistinen V.
        • Miettinen A.
        • Tornroth T.
        • Seppala I.J.
        Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis.
        J Exp Med. 1992; 175: 939-950
        • Jokiranta T.S.
        • Solomon A.
        • Pangburn M.K.
        • Zipfel P.F.
        • Meri S.
        Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H.
        J Immunol. 1999; 163: 4590-4596
        • Xu W.
        • Wang Y.H.
        • Fan L.
        • et al.
        Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia.
        Leuk Res. 2011; 35: 1060-1065
        • Hill P.A.
        • Firkin F.
        • Dwyer K.M.
        • Lee P.
        • Murphy B.F.
        Membranoproliferative glomerulonephritis in association with chronic lymphocytic leukaemia: a report of three cases.
        Pathology. 2002; 34: 138-143